CANCER GENE	<b>ETICS REC</b>	UISIT	ION – Hema	atolog	gic Neoplasia	
Hamilton Regional Laboratory Medicine			Patient Information Clear Form			
			*Name (print):			
Program			Surname, First Name *DOB (DD/MM/YYY	V)·	* <b>Sex</b> : 🗆 M 🗆 F 🗆 Other	
Juravinski Hospital			• • •	.,.		
Clinical Genetics Laboratory - Room H2-19A			*Health Card No.: *Mandatory Information. Specimen cannot be processed without this data.			
711 Concession Street, Hamilton, ON L8V IC3						
Phone: (905) 521-2100 x73707			Note: Specimen collection is NOT completed at this lab. Please proceed to any community lab for blood draw.			
Email: geneticsmailbox@hhsc.ca			•	ommunity	lab for blood draw.	
Reports To:			al Copies To:		Please see the HRLMP Laboratory	
*Ordering Physician:						
Address:		Address:			testing information	
*Phone: Fax:		*Phone:			https://ltig.hrlmp.ca/	
Physician Signature:						
Specimen Submitted:	Urgent (	Routine	For all requests a	and inquirie	es: <u>geneticsmailbox@hhsc.ca</u>	
Date of sample: (DD/MM/YYYY):			esh aspirate in tubes as		•	
Time:			L unless otherwise indic I in the laboratory with		6 mL if multiple tests requested)	
Location/Ward:			address above. Do not			
DIAGNOSTIC TESTING Please ta	ke care in sending	g the correc	t sample type. Impro	per sample	es will lead to delays/cancellation.	
MYELOID			MPHOID		LYMPHOPROLIFERATIVE NEOPLASM	
*Testing will be performed upon confirmation of diagnosis	ALL (sodium Karyotype		TA bone marrow)		(EDTA bone marrow, peripheral blood or FFPE tissue curls)	
<b>AML</b> (sodium heparin & EDTA bone marrow)	<ul> <li>RNA Fusion Gene Panel, if dx confirmed</li> </ul>				B-cell rearrangement PCR	
■ Karyotype	<b>MM</b> (sodium	heparin bone	e marrow)		T-cell rearrangement PCR	
<ul> <li>RNA Fusion Gene Panel*</li> <li>DNA Myeloid Panel/NGS*</li> </ul>	<ul> <li>FISH panel, if dx confirmed</li> </ul>				CHIMERISM	
		CLL (sodium heparin peripheral blood or bone mar				
<b>MDS or MDS/MPN</b> (sodium heparin & EDTA bone marrow)		el, if dx confirn			Pre-BMT (EDTA peripheral blood)	
■ Karyotype	blood)	eukemia (EL	DTA bone marrow or perip	oheral	Donor Donor	
<ul> <li>NGS*</li> <li>For suspected or confirmed MPN,</li> </ul>	BRAF cod	<ul> <li>BRAF codon V600 mutation</li> </ul>			□ Same Sex Donor	
please use the MPN boxes below for testing.		•	parin bone marrow)		Opposite Sex Donor	
OTHER	<ul> <li>If dx confirmed</li> <li>Testing will NOT be performed unless probe(s) selected.</li> </ul>			Recipient		
Karyotype Only (sodium heparin bone	□ MYC (8q24) -		□ ALK (2p23) – Anaplastic LCL		DAY 0 =	
marrow) <u>Please provide clinical information:</u>		□ BCL2 (18q21.33) – □ MALT1 (18q21) – Marginal Follicular/DLBCL Zone			<b>Post-BMT</b> (16 mL EDTA peripheral blood)	
□ BCL6 (3q27) – DLE			] CCND1 (11q13) — Mant	tle Cell	No. days post-transplant:	
SUSPECTED MYOPROLI		CON	NFIRMED MYELOPROLIFERATIVE			
□ JAK2 V617F and CALR (EDTA peripheral blo	od or bone marrow	v), please spe	ecify+:		NEOPLASM	
□ Unexplained abnormal blood counts: □ Leukocyte count ≥ 11 x 10 <sup>9</sup> /L	□ Unexplained abnormal blood counts: □ Leukocyte count ≥ 11 x 10 <sup>9</sup> /L					
□ Hemoglobin concentration ≥ 160			Confirmed MPN/MF			
□ Platelet count ≥ 400 x 10 <sup>9</sup> /L				<ul> <li>NGS Panel (EDTA bone marrow (preferred) or blood)**</li> <li>** NGS is available for confirmed MF or triple</li> </ul>		
<ul> <li>Unexplained unusual site thrombosis</li> <li>Unexplained hepatosplenomegaly and/or leukoerythroblastic blood film</li> </ul>				negative PV/ET		
CML - BCR::ABL1 (EDTA peripheral blood or	+.		Karyotype (sodium heparin bone marrow (preferred) or blood)			
□ Leukocyte count ≥ 11 x 10 <sup>9</sup> /L with left shift						
□ Leukocyte count $\ge$ 11 x 10 <sup>9</sup> /L with left shift □ Platelet count $\ge$ 400 x 10 <sup>9</sup> /L with basophilia +Test requests without a relevant indication selected will not be processed. For other indications, please email the laboratory.					** Please note, a pathology report is required to activate NGS. Please submit this with the requisition,	
□ <b>Karyotype</b> (sodium heparin peripheral bloc	-		or email	to geneticsmailbox@hhsc.ca when		
Hypereosinophilia FISH Panel, if dx confirmed (sodium heparin periphere)			l or bone marrow)	e. NGS will <u>not</u> be activated for this indication an appropriate report.		
MPL (EDTA bone marrow ONLY)				without		
GENETICS LAB						
USE ONLY: Entered by:	Checked by:		; BM or PB: x	_ mL NaHe	p, x mL EDTA Version date: CANGEN_HEMA_June202	

# **CANCER GENETICS REQUISITION – Hematologic Neoplasia**

## Hamilton Regional Laboratory Medicine Program

#### Juravinski Hospital

Clinical Genetics Laboratory - Room H2-19A 711 Concession Street, Hamilton, ON L8V IC3 Phone: (905) 521-2100 x73707

Email: geneticsmailbox@hhsc.ca

### **Patient Information**

\*Name (print): Surname, First Name

\*DOB (DD/MM/YYYY):

\***Sex**:  $\Box$  M  $\Box$  F  $\Box$  Other

#### \*Health Card No.:

\*Mandatory Information. Specimen cannot be processed without this data.

Note: Specimen collection is NOT completed at this lab. Please proceed to any community lab for blood draw.

Reports To:	ts To:		Copies To:	Please see the HRLMP Laboratory				
*Ordering Physician:		Name:		Test Information Guide (LTIG) for				
Address:		Address:		complete sample requirements and				
*Phone: Fax:		*Phone:		testing information https://ltig.hrlmp.ca/				
Physician Signature:								
Specimen Submitted:	🗋 Urgent	C Routine	For all requests and inquiries: gen	eticsmailbox@hhsc.ca				
Date of sample: (DD/MM/YYYY):	Bone Marrow (2-4 mL fresh aspirate in tubes as indicated below)							
Time:		Peripheral Blood (4-8 mL unless otherwise indicated. Max 16 mL if multiple tests requested) I samples must be received in the laboratory within 48 hours of collection.						
Location/Ward:		t room temperature to address above. <u>Do not freeze or spin</u> .						
FOLLOW-UP TESTING Testing performed based on previous findings ONLY								
TREATMENT RESPONSE/DISEASE MONITORING								
Testing will be completed if there are previous relevant diagnostic findings. If genetic diagnostic findings were obtained externally, please include a copy								
of the report, or email report to geneticsmailbox@hhsc.ca. If our laboratory does not have access to the relevant report, testing may be discontinued.								
BCR::ABL1 p210 Follow-up, Quantitative PCR (8 ml EDTA peripheral blood or 2-4 ml EDTA bone marrow)								
FLT3 Follow-up (EDTA bone marrow or peripheral blood)								
NPM1 MRD - Type A Variant only (EDTA bone marrow or peripheral blood)								
NPM1 Follow-Up - Qualitative (Variants other than type A) (EDTA bone marrow or peripheral blood)								
Karyotype and/or molecular testing as indicated by diagnostic findings, please specify (sodium heparin for karyotype <u>and/or</u> EDTA bone marrow or peripheral blood for molecular):								
RELAPSE/PROGRESSION SUSPECTED								
$\Box$ Karyotype as indicated by diagnostic findin		(sodium heparin bone marrow or peripheral blood)						
Molecular testing (Qualitative RNA fusion gene by diagnostic findings) (EDTA bone marrow or peripheral blood) Fusion gene(s):								
<ul> <li>FLT3/NPM1 Relapse/Refractory (EDTA bone marrow or peripheral blood)</li> <li>Please note, NPM1 follow-up testing will only be completed if there are relevant diagnostic findings.</li> </ul>								
GENTICS LAB USE ONLY:								
Reception	Sample							
Entered by:	BM or PB							
Data entry checked by:	x	mL NaHep						
	x	ml FDTA		Varian data: CANCEN HEMA June2025				